NTRBW
Nutriband Inc - Warrants (30/09/2026) (NTRBW)
NASDAQ • $1.530.00%
- Symbol
- NTRBW
- Exchange
- NASDAQ
- Sector
- Industry
- Price
- $1.53
- Daily Change
- 0.00%
- Market Cap
- N/A
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $4.50
- 52W Low
- $0.80
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 1.93
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Company websiteResearch NTRBW on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.